Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2022 / Cilt: 56 - Sayı: 2

Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?

Sayfa
276–283
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A statistically significant relation was found between HE- and PHH3-based risk scores (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: In gastrointestinal stromal tumors (GIST), malignancy potential is determined by the prognostic disease risk stratification based on mitosis, tumor size, and location.
📊
Temel Bulgular & Veri:Phosphohistone H3 (PHH3) is an immunohistochemical marker showing mitotic activity in cells.
💡
Sonuç & Katkı:A statistically significant relation was found between HE- and PHH3-based risk scores (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2006 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: In gastrointestinal stromal tumors (GIST), malignancy potential is determined by the prognostic disease risk stratification based on mitosis, tumor size, and location. Phosphohistone H3 (PHH3) is an immunohistochemical marker showing mitotic activity in cells. In this study, we aimed to evaluate mitosis in GIST with PHH3, compare the results with hematoxylin and eosin (HE) stained slides, and examine its relationship with other prognostic data. Methods: Clinicopathological findings and survival were determined in GIST cases diagnosed between 2006 and 2017. The prognostic risk score was calculated according HE- and PHH3-based mitosis. The cases were classified as Group I: HE + and PHH3 + and Group II: HE + and PHH3–. They were also grouped as those diagnosed before and after 2012 and the staining results of HE and PHH3 were re-analyzed. Results: Ninety-eight cases were included in the study. Mitosis was detected with both HE and PHH3 in 63.3% of the cases (62/98 cases) (Group I) while in 36.7% of cases, it was detected with HE but not with PHH3 (Group II). In only two cases, the risk score changed with PHH3 (very low → intermedier grade). The ratio of HE + and PHH3 + cases in 2012 and after was significantly higher than HE + and PHH3 – cases. A statistically significant relation was found between HE- and PHH3-based risk scores (p

🔖

Bu Makaleye Atıf Yap

GÜL, A. E., SAKİN, A., GÜNDOĞAN, G. A., ERHAN, S. Ş., KANGAL, E., KESER, S. H., SENSU, S. (2022). Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 56 - Sayı: 2, 276–283. https://ajindex.com/articles/594593

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011;104:865–73
  2. Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, et al. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol 2014;74:883–98
  3. Pleşea IE, Chiuţu L, Bordu SI, Georgescu I, Georgescu EF, Ciobanu D, et al. Gastrointestinal stromal tumors - a clinical-morphological study on 15 cases. Rom J Morphol Embryol 2014;55:513–23
  4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83
  5. Dei Tos AP, Hornick JL, Miettinen M. Gastrointestinal stromal tumour. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of Tumours of the Digestive System. 5th ed. IARC Press: Lyon; 2019. p. 439–43
  6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–65
  7. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:1411–9
  8. Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki67 index in adrenocortical carcinoma. Mod Pathol 2014;27:1246– 54
  9. Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, et al. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol 2012;34:266–9
  10. Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach LM, Kerfoot CA. Level of phosphohistone H3 among various types of human cancers. BMJ Open 2012;2:e001071
  11. Chow KL, Tse KY, Cheung CL, Wong KW, Cheung AN, Wong RW, et al. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study. Histopathology 2017;70:746–55
  12. Shin Y, Hyeon J, Lee B, Ha SY, Hong ME, Do IG, et al. PHH3 as an ancillary mitotic marker in gastrointestinal stromal tumors. J Pathol Transl Med 2015;49:23–9
  13. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediategrade infiltrating astrocytomas. Am J Surg Pathol 2006;30:657– 64
  14. Liang YM, Li XH, Li WM, Lu YY. Prognostic s